Addex Partner Janssen Discontinues ADX71149 Epilepsy Treatment After Phase 2 Study
Author: Benzinga Newsdesk | July 22, 2024 02:12am
The decision follows top-line Phase 2 data announced on April 29, 2024, showing that adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.
Posted In: ADXN